Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a dose level and vaccination interval study of Ad26.COV2.S in adults and adolescents
2020-002584-63Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ad26.COV2.S with Placebo (2 arms). Primary endpoint: Serological response 28 days after Vaccination 2. Started Aug 2020; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002584-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002584-63.